Forschungs- und Innovationspreis für Urologische Onkologie
2024
Dr. med. Gamal Anton Wakileh, Ulm
„Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates“
PD Dr. med. habil. Markus Eckstein, Erlangen
„SpatialImmunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition“
2023
Dr. Niklas Klümper, Bonn
„Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance“
2022
Dr. Victor Schüttfort, Hamburg
„Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy“
2019
PD Dr. med. Wolfgang Fendler, Essen
„Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer - A Prospective Single-Arm Clinical Trial.”
2018
Martin Puhr, Innsbruck, Österreich
The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy
2017
PD Dr. Tobias Maurer, München
Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up
2016
Dr. Renate Pichler, Innsbruck
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-guérin therapy in bladder cancer
2015
PD Dr. Jörg Ellinger, Bonn
Identification of novel long non-coding RNAs in clear cell renal cell carcinoma
2014
J. Heinzelmann, Homburg/Saar
MicroRNAs with Prognostic Potential for Metastasis in Clear Cell Renal Cell Carcinoma: A Comparison of Primary Tumors and Distant Metastases
W. Jager, Mainz
Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach
2013
Heidegger, I., Innsbruck
Diverse Functions of IGF/Insulin Signaling in Malignant and Noncancerous Prostate Cells: Proliferation in Cancer Cells and Differentiation in Noncancerous Cells
2012
Hofer, J., Innsbruck
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21
2011
Ohlmann, C.-H., Markert, E., Gerharz, M., Dienes, H.-P., Stockle, M., Engelmann, U., Heidenreich, A.
Improving the Efficacy of Targeted Trials by Multiple-marker Analysis in Castrationresistant Prostate Cancer
Roos, F., R., Roberts, A. M., Hwang, I. L., Moriyama, E. H., Evans, A. J., Sybingco, S., Warson, I. R., Carneiro, L. A. M., Gedye, C., Girardin, S., E., Ailles, L. E., Jewett, M. A S., Milosevic, M., Wilson, B. C., Bell, J. C., Der, S. D., Ohh, M.
Oncolytic Targeting of Renal Cell Carcinoma via Encephalomyocarditis Virus
2010
Kruck, S., Bedke, J., Hennenlotter, J., Ohneseit, P.A., Kuehs, U., Senger, E., Sievert, K.-D., Stenzl, A., Tübingen Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression
2009
Tezval, H., Hannover
Urocortin and corticotropin releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation
2008
Grünwald, V., De Graffenried, L., Russel, D., Friedrichs, W.E., Ray, R.B., Hidalgo, M., Hannover
Inhibitors of m TOR Reverse Doxorubicin Resistance Conferred by PTEN Status in Prostate Cancer Cells